Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
39 hedge funds and large institutions have $10.8M invested in Bellerophon Therapeutics, Inc. in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
5% more funds holding
Funds holding: 37 → 39 (+2)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
40% less capital invested
Capital invested by funds: $18.2M → $10.8M (-$7.37M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
+$682K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$342K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$139K |
| 4 |
LCM
Laurion Capital Management
New York
|
+$139K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMVA
New Mountain Vantage Advisers
New York
|
-$5.27M |
| 2 |
TI
Telemetry Investments
New York
|
-$208K |
| 3 |
State Street
Boston,
Massachusetts
|
-$157K |
| 4 |
Two Sigma Investments
New York
|
-$131K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$121K |
BLPH Hedge Fund Activity: Q1 2021 in Review
39 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2021, worth a combined $10.8M — down 40% from $18.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BLPH positions and 6 closed out — a net gain of 2 holders — while 11 added to existing stakes and 12 trimmed.
The largest buyer was CAAS Capital Management, opening a new position worth an estimated $682K. The largest seller was New Mountain Vantage Advisers, cutting an estimated $5.27M.
- 39 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2021, up from 37 in Q4 2020.
- Funds reported $10.8M of Bellerophon Therapeutics, Inc. stock for Q1 2021, down 40% quarter-over-quarter.
- 8 funds opened new Bellerophon Therapeutics, Inc. positions in Q1 2021 and 6 closed out, a net change of +2 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q1 2021 was CAAS Capital Management, an estimated $682K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q1 2021 was New Mountain Vantage Advisers, an estimated $5.27M sold.
Based on aggregated 13F filings for Q1 2021.